logo-loader
viewAstraZeneca

AstraZeneca partner gets approval to market its roxadustat drug as an anaemia treatment in China

The FTSE 100-listed drugmaker said its partner FibroGen China received marketing authorisation from the Chinese National Medical Products Administration for orally-administered roxadustat

China
AstraZeneca said it and FibroGen expects to launch roxadustat in China in the second half of 2019

AstraZeneca PLC (LON:AZN.LN) has got approval in China to market its roxadustat drug as a treatment for patients with anaemia who have chronic kidney disease and are on dialysis.

The FTSE 100-listed drugmaker said its partner FibroGen China, a subsidiary of FibroGen Inc. received marketing authorisation from the Chinese National Medical Products Administration for orally-administered roxadustat.

READ: AstraZeneca’s Imfinzi cancer drug fails in another late-stage trial

The firm said it will be responsible for bringing the drug to market in the country, while FibroGen will manage the processes of manufacturing, regulation and continued research.

AstraZeneca said it expects to launch roxadustat in China in the second half of 2019.

Sean Bohen, AstraZeneca’s executive vice president, Global Medicines Development and chief medical officer, said: "Roxadustat is a long-awaited, first-in-class medicine for patients with anaemia in chronic kidney disease that are on dialysis.

“This first approval of roxadustat in China is a significant step towards achieving our ambition to transform care in a condition where prevalence in China is increasing."

Quick facts: AstraZeneca

Price: 6815 GBX

LSE:AZN
Market: LSE
Market Cap: £89.41 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Panther Metals set up for its next strategic move with an 'enviable'...

Panther Metals plc's (LON:PALM) Darren Hazelwood and Kerim Sener introduce the explorer to Proactive London's Andrew Scott. In Canada recent field activities have returned some 'exceptional' results including significant soil gold anomalies in four major target areas. Meanwhile in...

12 hours, 20 minutes ago

2 min read